Home Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes
 

Keywords :   


Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes

2014-09-17 15:31:00| Merck.com - Corporate News

Dateline City: WHITEHOUSE STATION, N.J. Omarigliptin significantly reduced HbA1c levels compared to placebo WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of the first data from the Phase 3 clinical development program for omarigliptin, Mercks investigational once-weekly DPP-4 inhibitor for the treatment of type 2 diabetes. In a study in Japanese patients, omarigliptin provided comparable efficacy and tolerability to Mercks once-daily DPP-4 inhibitor JANUVIA (sitagliptin) 50 mg, which is the standard starting dose for sitagliptin in Japan. Language: English Contact: MerckMedia:Pam Eisele, +1 (267) 305-3558Michael Close, +1 (267) 305-1221 or +1 (310) 617-1067orInvestors:Justin Holko, +1 (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: for type data japanese

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
05.11Boeing strike ends as workers back 38% pay rise deal
05.11Tropical Storm Rafael Public Advisory Number 6A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Graphics
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 6
More »